Logo image of IMRX

IMMUNEERING CORP - CLASS A (IMRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IMRX - US45254E1073 - Common Stock

6.73 USD
-0.08 (-1.17%)
Last: 12/26/2025, 9:55:40 PM
6.8601 USD
+0.13 (+1.93%)
After Hours: 12/26/2025, 9:55:40 PM
Fundamental Rating

3

Overall IMRX gets a fundamental rating of 3 out of 10. We evaluated IMRX against 530 industry peers in the Biotechnology industry. IMRX has a great financial health rating, but its profitability evaluates not so good. IMRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IMRX had negative earnings in the past year.
IMRX had a negative operating cash flow in the past year.
IMRX had negative earnings in each of the past 5 years.
In the past 5 years IMRX always reported negative operating cash flow.
IMRX Yearly Net Income VS EBIT VS OCF VS FCFIMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

IMRX's Return On Assets of -25.93% is fine compared to the rest of the industry. IMRX outperforms 70.38% of its industry peers.
With a decent Return On Equity value of -27.41%, IMRX is doing good in the industry, outperforming 78.68% of the companies in the same industry.
Industry RankSector Rank
ROA -25.93%
ROE -27.41%
ROIC N/A
ROA(3y)-69.7%
ROA(5y)-54.72%
ROE(3y)-84.13%
ROE(5y)-64.35%
ROIC(3y)N/A
ROIC(5y)N/A
IMRX Yearly ROA, ROE, ROICIMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMRX Yearly Profit, Operating, Gross MarginsIMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, IMRX has more shares outstanding
Compared to 5 years ago, IMRX has more shares outstanding
IMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMRX Yearly Shares OutstandingIMRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
IMRX Yearly Total Debt VS Total AssetsIMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 18.59 indicates that IMRX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 18.59, IMRX belongs to the top of the industry, outperforming 88.30% of the companies in the same industry.
There is no outstanding debt for IMRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.59
ROIC/WACCN/A
WACCN/A
IMRX Yearly LT Debt VS Equity VS FCFIMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

IMRX has a Current Ratio of 24.00. This indicates that IMRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 24.00, IMRX belongs to the best of the industry, outperforming 97.17% of the companies in the same industry.
IMRX has a Quick Ratio of 24.00. This indicates that IMRX is financially healthy and has no problem in meeting its short term obligations.
IMRX's Quick ratio of 24.00 is amongst the best of the industry. IMRX outperforms 97.17% of its industry peers.
Industry RankSector Rank
Current Ratio 24
Quick Ratio 24
IMRX Yearly Current Assets VS Current LiabilitesIMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

IMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.64%, which is quite good.
EPS 1Y (TTM)9.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.29% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.57%
EPS Next 2Y9.42%
EPS Next 3Y6.69%
EPS Next 5Y11.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMRX Yearly Revenue VS EstimatesIMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
IMRX Yearly EPS VS EstimatesIMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMRX Price Earnings VS Forward Price EarningsIMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMRX Per share dataIMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.42%
EPS Next 3Y6.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IMMUNEERING CORP - CLASS A

NASDAQ:IMRX (12/26/2025, 9:55:40 PM)

After market: 6.8601 +0.13 (+1.93%)

6.73

-0.08 (-1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)N/A N/A
Inst Owners48.39%
Inst Owner Change577.53%
Ins Owners9.4%
Ins Owner Change1.64%
Market Cap434.56M
Revenue(TTM)N/A
Net Income(TTM)-62.50M
Analysts85
Price Target17.17 (155.13%)
Short Float %13.75%
Short Ratio6.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.23%
Min EPS beat(2)4.96%
Max EPS beat(2)5.5%
EPS beat(4)3
Avg EPS beat(4)2.37%
Min EPS beat(4)-22.81%
Max EPS beat(4)21.82%
EPS beat(8)6
Avg EPS beat(8)3.76%
EPS beat(12)10
Avg EPS beat(12)7.53%
EPS beat(16)12
Avg EPS beat(16)6.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1%
PT rev (3m)31.51%
EPS NQ rev (1m)27.69%
EPS NQ rev (3m)10.48%
EPS NY rev (1m)9.22%
EPS NY rev (3m)9.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.91
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0
BVpS3.53
TBVpS3.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.93%
ROE -27.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.7%
ROA(5y)-54.72%
ROE(3y)-84.13%
ROE(5y)-64.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.61%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24
Quick Ratio 24
Altman-Z 18.59
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)127.9%
Cap/Depr(5y)150.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.45%
EPS Next Y28.57%
EPS Next 2Y9.42%
EPS Next 3Y6.69%
EPS Next 5Y11.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.81%
EBIT Next 3Y-26.85%
EBIT Next 5Y-22.09%
FCF growth 1Y-1.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.2%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNEERING CORP - CLASS A / IMRX FAQ

What is the ChartMill fundamental rating of IMMUNEERING CORP - CLASS A (IMRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMRX.


Can you provide the valuation status for IMMUNEERING CORP - CLASS A?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNEERING CORP - CLASS A (IMRX). This can be considered as Overvalued.


How profitable is IMMUNEERING CORP - CLASS A (IMRX) stock?

IMMUNEERING CORP - CLASS A (IMRX) has a profitability rating of 1 / 10.


How financially healthy is IMMUNEERING CORP - CLASS A?

The financial health rating of IMMUNEERING CORP - CLASS A (IMRX) is 8 / 10.


Can you provide the expected EPS growth for IMRX stock?

The Earnings per Share (EPS) of IMMUNEERING CORP - CLASS A (IMRX) is expected to grow by 28.57% in the next year.